Primary diffuse large B-cell lymphoma of the mandible by Siqueira, Juliana Mota et al.
Autopsy and Case Reports. ISSN 2236-1960. Copyright © 2019. This is an Open Access article distributed 
under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium provided the article is properly cited.
a A.C. Camargo Câncer Center, Stomatology Department. São Paulo, SP, Brazil
b University of Campinas – UNICAMP, Piracicaba Dental School, Department of Oral Diagnosis. Piracicaba, SP, Brazil.
c A.C. Camargo Cancer Center, Pathologic Anatomy Department. São Paulo, SP, Brazil
Primary diffuse large B-cell lymphoma of the mandible
Juliana Mota Siqueiraa , Patrícia Maria Fernandesa,b ,  
Andrea Cruz Ferraz de Oliveirac , José Vassalloc , Fábio de Abreu Alvesa , 
Graziella Chagas Jaguara 
How to cite: Siqueira JM, Fernandes PM, Oliveira ACF, Vassallo J, Alves FA, Jaguar GC. Primary diffuse large B-cell lymphoma 
of the mandible. Autops Case Rep [Internet]. 2019 Jul-Sep;9(3):e201910. https://doi.org/10.4322/acr.2019.109
Article / Clinical Case Report
Abstract
Primary intraosseous non-Hodgkin lymphoma in the mandible is uncommon, representing about 0.6% of all extranodal 
lymphomas. We present the case of a 51-year-old male with a 4-month complaint of mandibular swelling and paresthesia, 
which had been previously submitted to an unsuccessful periodontal treatment. The intra-oral evaluation showed an 
extensive swelling with teeth mobility in the right mandible body. The panoramic radiography and computed tomography 
images showed an extensive osteolytic lesion. An incisional biopsy was performed and the histopathological and 
immunohistochemical analysis established the diagnosis of diffuse large B-cell lymphoma. The treatment included six 
cycles of chemotherapy with complete remission. The patient is under the seventh month of follow-up with no evidence 
of relapse. Although uncommon in the oral cavity, lymphoma should be considered in the differential diagnosis. 
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INTRODUCTION
Lymphomas are divided into Hodgkin lymphoma 
(HL) and non-Hodgkin lymphoma (NHL). Approximately 
48% of the NHLs occur in the extranodal sites, and 
after the gastrointestinal tract, the head and neck is 
the most common location.1,2
In the head and neck, NHL mostly involves the 
Waldeyer ring,3 followed by the other soft tissues of 
this region, such as the tongue and the floor of the 
mouth. NHLs also sporadically occur in the bone tissue 
of the head and neck.4 Primary NHL of the mandible 
is less frequent than the maxillary involvement,5 and 
it can appear as a solitary lesion or resorption of the 
margin of the alveolar bone, resembling periodontal 
disease or cystic lesions.
The clinical features, such as swelling, pain, 
paresthesia, tooth mobility, or pathologic fracture, 
are frequent but non-specific, which may lead to 
misdiagnosis. In the literature, several reports illustrate 
the challenging diagnosis of oral lymphoma.6-8 Here, 
we present an uncommon case of primary NHL of 
the mandible, which was initially misdiagnosed as 
periodontal disease.
CASE REPORT
A 51-year-old male patient was referred to the 
Stomatology Department complaining of mandibular 
swelling and paresthesia in the right body of mandible 
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over the past 4 months. He reported a periodontal 
treatment followed by a first molar extraction, 1 month 
prior, at the same site. His medical history revealed 
prostatic cancer surgically treated 3 years earlier with 
no evidence of any metastasis during the follow-up.
An intraoral examination revealed an extensive 
mass with fibrous consistency and teeth mobility in the 
posterior region of the right mandible extending from 
the canine to the second molar (Figure 1). Extraoral 
examination showed facial asymmetry due to swelling 
on the right body of the mandible.
The panoramic radiography showed an extensive 
radiolucent image, with a line of fracture in the 
posterior region of the right mandible (Figure 2A). 
The computed tomography (CT) images showed a 
45 × 11 mm osteolytic lesion around the mandibular 
canal and the mental foramen, which reabsorbed the 
vestibular cortical bone (Figure 2B).
Considering the aggressive clinical signs, the 
main clinical hypothesis was a malignant tumor. 
An incisional biopsy was performed under local 
anesthesia. The histological examination of the biopsy 
evidenced a dense proliferation of neoplastic cells at 
the reticular dermis (Figure 3A). At high power, the 
neoplastic cells showed large pleomorphic cells with 
Figure 1. Intraoral examination shows a diffuse swelling 
in the right vestibular mucosa of the mandible from the 
first premolar to the second molar.
Figure 2. A – Panoramic radiography showing a radiolucent area in the right side of the mandible from the first 
premolar to the second molar. Also, it is possible to observe a line of fracture. B – facial CT, axial plane, showing a 
rupture of the cortical bone. C – PET/CT scan exhibiting an uptake area in the right mandible body.
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nuclear atypia, prominent nucleoli, and the presence 
of mitoses, consistent with lymphoid neoplasia 
(Figure 3B). The tumor cells showed immunopositivity 
for CD20 (Figure 4A), CD5 (Figure 4B), and no 
expression to CD10 (Figure 4C). According to these 
findings, the diagnosis of diffuse large B-cell lymphoma 
(DLBCL) non-germinal center type was established.
After this diagnosis, the patient was referred to the 
Hematology Department and underwent a full-body 
positron emission tomography scan showing a high 
metabolic activity extra nodal with a standardized 
uptake value (SUV) of 17.7 in the right mandible and 
another in the right submandibular area with an SUV 
of 2.5 (Figure 2C). No tumor activity was noted in other 
Figure 3. Photomicrographs of the biopsy specimen showing in A and B a dense proliferation of neoplastic cells 
in the submucosa (H&E, original magnification 10X (A), 20X (B). At higher power, it is noticed a sheet of atypical 
lymphocytic cells showing prominent and hyperchromatic nuclei besides atypical mitosis (C and D) (H&E, original 
magnification 40X).
Figure 4. Immunohistochemical panel showing the neoplastic cells with a diffuse expression of CD20 (A) and 
CD5 (B), and no expression of CD10 (C) – (original magnification 20X).
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sites. The patient was classified in Stage I Ann Arbor 
with a localized involvement of a single extra-lymphatic 
organ site (stage IE).
The patient underwent six cycles of prednisone, 
vincristine, cyclophosphamide, doxorubicin, and 
rituximab (R-CHOP) followed by two cycles of high-dose 
methotrexate (HD-MTX; 3.5 g/m2). The complete 
remission was verified in the CT scan after four cycles 
of R-CHOP (Figure 5A), and the radiographic exams 
showed a consolidation of fracture (Figure 5B). In the 
7-month follow-up, the patient did not present any 
clinical signs and symptoms of the tumor, and no teeth 
mobility was found (Figure 6).
DISCUSSION
According to the project of the International 
Agency for Research on Cancer (IARC)-GLOBOCAN, 
509,590 new cases of NHL and 248,724 deaths were 
estimated to occur in 2018, worldwide.9 The incidence 
rates for NHL are increasing annually and represent 
the eleventh most frequent type of cancer in Brazil.8 
In the oral cavity, lymphoma can appear anywhere 
in the mouth but predominates on the hard palate, 
gingiva, and tongue.1 The mandible is an infrequent 
localization of primary osseous NHL.
Although rare, these neoplasms are generally 
diagnosed in the jawbones of the adults in the 
fourth and fifth decade of life. The oral swelling 
and pain are the most frequent clinical features, 
which are often associated with teeth mobility 
and paresthesia.1 Radiographically, intraosseous 
involvement is represented by osteolytic lesions, 
unilocular or multilocular, with poorly defined borders.3 
However, these signs may resemblance other diseases, 
such as benign or malignant tumors, which hampers 
the correct diagnosis. Based on the aggressive 
clinical/radiographic findings, the lesion was initially 
considered to be a malignant tumor.
DLBCL represents the most common type of 
NHL, accounting for 40% off all cases. DLBCL is a 
heterogeneous entity with varied clinical features, 
morphology, immunohistochemistry, and prognosis.10,11 
These differences should be carefully analyzed in order 
to achieve successful management.
As far as the subclassification of DLBCL is 
concerned, this entity can be characterized in three 
forms: germinal center B-cell, activated B-cell or does 
not fit into any classification. In the case presented 
here, the tumor cells showed negativity for CD10 and 
BCL6, being classified according to the Hans algorithm 
as a non-germinal center subtype.12
Regarding the differential diagnosis, it is important 
to note that Burkitt lymphoma (BL) may share some 
Figure 5. Post-treatment image of the panoramic radiography showing fracture healing (A) and computed 
tomography displaying the new formed cortical bone (B).
Figure 6. Intraoral examination after the treatment 
showing complete remission of the initial lesion.
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histopathological features with the DLBCL and it is 
imperative to differentiate them once the treatment is 
distinct. In the case reported here, the c-MYC, usually 
present in BL, was positive in less than 10% of the 
cells, refuting BL as a possible diagnosis.13
Treatment for DLBCL consists of a standard R-CHOP 
therapy, which has a cure rate of 60%. Currently, the 
improved management of the high-risk subgroup of 
patients with specific histologic, immunophenotypic, 
and molecular features determines which treatment 
will achieve the better prognosis.14 The CD5 positivity 
represents only 5% to 10% of DLBCL cases.11 
A recent study of DLBCL patients treated with 
R-EPOCH (rituximab, etoposide, prednisone, vincristine, 
cyclophosphamide, and doxorubicin) showed that CD5 
expression is an independent prognostic factor for 
poorer overall survival.12
The CD5 positivity in DLBCL is also associated with 
a frequent central nervous system (CNS) relapse rate. 
It is suggested that HD-MTX may be an efficacious 
treatment to prevent CNS relapse in CD5+ DLBCL 
patients.15 In this current case, the patient presented 
positivity for CD5 and received HD-MTX (3.5 g/m2) to 
CNS prophylaxis.
Due to these various clinical manifestations NHL 
in the oral cavity, we emphasize that it is crucial for 
the dentist to be aware of the clinical/radiographic 
features of intraosseous NHL and refer these patients 
to a specialized service in order to achieve an early 
diagnosis.
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